Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

R. Daifuku; Edward A Panacek; K. Haenftling; W. K. Swenson; A. W. Prescott; J. L. Johnson

Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

R. Daifuku, Edward A Panacek, K. Haenftling, W. K. Swenson, A. W. Prescott, J. L. Johnson

Research output: Contribution to journal › Article › peer-review

Abstract

MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.

Original language	English (US)
Pages (from-to)	36-39
Number of pages	4
Journal	Human Antibodies and Hybridomas
Volume	4
Issue number	1
State	Published - 1993
Externally published	Yes

ASJC Scopus subject areas

Immunology

Fingerprint Dive into the research topics of 'Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis'. Together they form a unique fingerprint.

Cite this

@article{46195ef6d02d4ea19ed4ef7d25d875ed,

title = "Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis",

abstract = "MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.",

author = "R. Daifuku and Panacek, {Edward A} and K. Haenftling and Swenson, {W. K.} and Prescott, {A. W.} and Johnson, {J. L.}",

year = "1993",

language = "English (US)",

volume = "4",

pages = "36--39",

journal = "Human Antibodies",

issn = "1093-2607",

publisher = "IOS Press",

number = "1",

}

TY - JOUR

T1 - Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

AU - Daifuku, R.

AU - Panacek, Edward A

AU - Haenftling, K.

AU - Swenson, W. K.

AU - Prescott, A. W.

AU - Johnson, J. L.

PY - 1993

Y1 - 1993

N2 - MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.

AB - MAB-T88 is a human monoclonal IgM antibody directed at the lipopolysaccharide of gram-negative bacteria. A protocol was designed to identify a group of septic patients with a very high likelihood of gram-negative bacteremia. All 6 patients entered in the protocol had a gram-negative source, and 4 of 6 had gram-negative bacteremia. In this patient population, MAB-T88 was shown to be safe with an effective half-life of 19.1 hours.

UR - http://www.scopus.com/inward/record.url?scp=0027497685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027497685&partnerID=8YFLogxK

M3 - Article

C2 - 8431557

AN - SCOPUS:0027497685

VL - 4

SP - 36

EP - 39

JO - Human Antibodies

JF - Human Antibodies

SN - 1093-2607

IS - 1

ER -

Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis

Abstract

ASJC Scopus subject areas

Other files and links

Cite this